logo
  

New Jersey Resources Lifts FY Earnings Guidance On Growth At NJR Energy

New Jersey Resources Corp (NJR)) on Tuesday said it is raising its fiscal 2015 net financial earnings guidance to a split-adjusted range of $1.60 to $1.70 per basic share, from the prior guidance of $1.45 to $1.55 per share.

Analysts polled by Thomson Reuters expect the company to report earnings of $1.53 per share for 2015. Analysts' estimates typically exclude special items.

The company said the increased guidance is due mainly to better-than-anticipated results at NJR Energy Services, its wholesale provider of physical natural gas services.

Also the company's regulated utility business, New Jersey Natural Gas, has shown strong results, as has NJR Clean Energy Services, its unregulated distributed power subsidiary, and midstream asset segment, NJR Midstream.

The company said it expects New Jersey Natural Gas to be the largest contributor to fiscal 2015 net financial earnings. Steady growth at this division continues to be supported by customer growth in both new construction and conversion markets and regulatory initiatives that earn current returns.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates. Dr. Reddy's Laboratories Ltd. is recalling six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg to the consumer level. According to the U.S. Food and Drug Administration, the recall was due to powder discoloration in some packets leading to decreased potency.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
RELATED NEWS
Follow RTT